Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Executive Summary

• Cardiol Therapeutics received a Notice of Allowance for its U.S. patent application covering “Cannabidiol Compositions for Use in Treating Heart Conditions,” extending protection for CardiolRx™ and CRD‑38 to October 2040.
• The allowance coincides with the company’s U.S. Orphan Drug Designation for pericarditis and supports upcoming clinical milestones, including first‑in‑human testing of CRD‑38 and presentations of Phase II ARCHER data.
• Management highlighted that the expanded IP portfolio strengthens Cardiol’s market position and underpins its late‑stage anti‑inflammatory/anti‑fibrotic heart disease programs (MAVERIC and ARCHER).

Key Details

• Patent Scope: Broad U.S. protection for use of CardiolRx™ and CRD‑38 in treating/preventing heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti‑cancer therapies, and atherosclerosis.
• Expiration: Patent term runs to October 2040, providing up to 15 years of exclusivity beyond filing date.
• Regulatory Milestones: Company also holds U.S. Orphan Drug Designation for pericarditis; the new patent complements this status.
• Clinical Pipeline Impact:
• Preparing first‑in‑human (FIH) study of CRD‑38, a subcutaneous therapy for inflammatory heart disease including heart failure.
• Phase II ARCHER trial topline results to be presented at the European Society of Cardiology Annual Meeting (Nov 29, Trieste, Italy).
• Ongoing enrollment in pivotal Phase III MAVERIC trial for recurrent pericarditis.
• Quotes:
• “This important milestone extends our I.P. protection to the world’s largest pharmaceutical market,” – David Elsley, President & CEO.
• “We now look forward to presenting the comprehensive data from ARCHER… and providing an update on our pivotal Phase III MAVERIC trial,” – Dr. Andrew Hamer, CMO & Head of R&D.

Notable Quotes

• David Elsley (President & CEO): “Together with our U.S. Orphan Drug Designation for pericarditis, this new patent allowance fortifies Cardiol’s market position and I.P. portfolio… By securing this protection through late 2040, we are solidifying a strong foundation to support our global clinical and commercial strategy.”
• Dr. Andrew Hamer (CMO): “We now look forward to presenting the comprehensive data from ARCHER… and providing insights into potential new development opportunities in myocarditis, as well as the positive implications for our CRD‑38 program in heart failure.”